| Executive Summary: | Impel is a specialty biopharmaceutical company focused on delivering pharmaceuticals to the brain using revolutionary intranasal delivery technology. Currently 98% of small molecules and 100% biologics are prevented from reaching the brain due to a physiological phenomenon known as the blood-brain-barrier (BBB). The upper olfactory region of the nasal cavity offers the only location in the body where the BBB can be bypassed. Depositing aerosolized drug on the upper region of the nasal cavity causes rapid and direct distribution into the brain and the CNS with little absorption into the systemic blood stream. This disruptive drug delivery technology will solve the largest problem in the CNS market and lead to a paradigm shift in neurological drug development.
Impel’s POD (Pressurized Olfactory Delivery) device resembles a conventional over-the-counter nasal spray. The POD uses dynamic airflow to deliver biopharmaceuticals to the brain via the upper nasal cavity, bypassing the BBB without requiring chemical modification of the drug molecule or proprietary formulation additives. This offers pharmaceutical firms the ability to reformulate their current products for better performance, repurpose existing compounds, and rescue compounds that have been dropped from their pipeline due to an inability to cross the BBB. |
